VT ablation

New developments and approaches

Zhiyu Ling, Adithya Hari, Harikrishna Tandri

Research output: Contribution to journalArticle

Abstract

Over the past decade, catheter ablation has emerged as an important therapeutic option for ventricular tachycardia (VT) in both patients with and without structural heart disease. In patients without structural heart disease, catheter ablation serves as sole therapy for the treatment of VT. For those with structural heart disease, VT ablation has generally been reserved for patients who experience ICD therapies, and particularly those who fail antiarrhythmic agents. With the growing number of patients with implantable devices as well as improvements in heart failure therapy resulting in improved survival among ICD patients, the overall number of patients needing therapy for VT continues to increase. The past years have witnessed significant advances in our understanding of the arrhythmic substrate in various cardiomyopathies, resulting in substrate-based approaches for targeted VT ablation. Further, the growth in better technologies and techniques for VT ablation, such as the use of percutaneous epicardial ablation, the innovation of multielectrode catheters for rapid mapping, the use of intracardiac echocardiography (ICE) for mapping unusual sites, and activation and entrainment mapping of previously unmappable VTs assisted by mechanical circulatory support devices, has overcome the limitations and greatly improved the success rates of catheter ablation. This review summarizes recent advances and novel approaches in both technology and techniques for catheter ablation of ventricular tachycardia.

Original languageEnglish (US)
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume16
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Ventricular Tachycardia
Catheter Ablation
Heart Diseases
Therapeutics
Cardiac Catheters
Technology
Equipment and Supplies
Cardiomyopathies
Echocardiography
Catheters
Heart Failure
Survival
Growth

Keywords

  • Arrhythmia
  • Catheter ablation
  • Heart failure
  • ICD failure
  • Intracardiac echocardiography
  • Ventricular tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

VT ablation : New developments and approaches. / Ling, Zhiyu; Hari, Adithya; Tandri, Harikrishna.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 16, No. 4, 2014.

Research output: Contribution to journalArticle

@article{3c88fbaf02b140dc8378edcd2f62c92f,
title = "VT ablation: New developments and approaches",
abstract = "Over the past decade, catheter ablation has emerged as an important therapeutic option for ventricular tachycardia (VT) in both patients with and without structural heart disease. In patients without structural heart disease, catheter ablation serves as sole therapy for the treatment of VT. For those with structural heart disease, VT ablation has generally been reserved for patients who experience ICD therapies, and particularly those who fail antiarrhythmic agents. With the growing number of patients with implantable devices as well as improvements in heart failure therapy resulting in improved survival among ICD patients, the overall number of patients needing therapy for VT continues to increase. The past years have witnessed significant advances in our understanding of the arrhythmic substrate in various cardiomyopathies, resulting in substrate-based approaches for targeted VT ablation. Further, the growth in better technologies and techniques for VT ablation, such as the use of percutaneous epicardial ablation, the innovation of multielectrode catheters for rapid mapping, the use of intracardiac echocardiography (ICE) for mapping unusual sites, and activation and entrainment mapping of previously unmappable VTs assisted by mechanical circulatory support devices, has overcome the limitations and greatly improved the success rates of catheter ablation. This review summarizes recent advances and novel approaches in both technology and techniques for catheter ablation of ventricular tachycardia.",
keywords = "Arrhythmia, Catheter ablation, Heart failure, ICD failure, Intracardiac echocardiography, Ventricular tachycardia",
author = "Zhiyu Ling and Adithya Hari and Harikrishna Tandri",
year = "2014",
doi = "10.1007/s11936-014-0297-2",
language = "English (US)",
volume = "16",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - VT ablation

T2 - New developments and approaches

AU - Ling, Zhiyu

AU - Hari, Adithya

AU - Tandri, Harikrishna

PY - 2014

Y1 - 2014

N2 - Over the past decade, catheter ablation has emerged as an important therapeutic option for ventricular tachycardia (VT) in both patients with and without structural heart disease. In patients without structural heart disease, catheter ablation serves as sole therapy for the treatment of VT. For those with structural heart disease, VT ablation has generally been reserved for patients who experience ICD therapies, and particularly those who fail antiarrhythmic agents. With the growing number of patients with implantable devices as well as improvements in heart failure therapy resulting in improved survival among ICD patients, the overall number of patients needing therapy for VT continues to increase. The past years have witnessed significant advances in our understanding of the arrhythmic substrate in various cardiomyopathies, resulting in substrate-based approaches for targeted VT ablation. Further, the growth in better technologies and techniques for VT ablation, such as the use of percutaneous epicardial ablation, the innovation of multielectrode catheters for rapid mapping, the use of intracardiac echocardiography (ICE) for mapping unusual sites, and activation and entrainment mapping of previously unmappable VTs assisted by mechanical circulatory support devices, has overcome the limitations and greatly improved the success rates of catheter ablation. This review summarizes recent advances and novel approaches in both technology and techniques for catheter ablation of ventricular tachycardia.

AB - Over the past decade, catheter ablation has emerged as an important therapeutic option for ventricular tachycardia (VT) in both patients with and without structural heart disease. In patients without structural heart disease, catheter ablation serves as sole therapy for the treatment of VT. For those with structural heart disease, VT ablation has generally been reserved for patients who experience ICD therapies, and particularly those who fail antiarrhythmic agents. With the growing number of patients with implantable devices as well as improvements in heart failure therapy resulting in improved survival among ICD patients, the overall number of patients needing therapy for VT continues to increase. The past years have witnessed significant advances in our understanding of the arrhythmic substrate in various cardiomyopathies, resulting in substrate-based approaches for targeted VT ablation. Further, the growth in better technologies and techniques for VT ablation, such as the use of percutaneous epicardial ablation, the innovation of multielectrode catheters for rapid mapping, the use of intracardiac echocardiography (ICE) for mapping unusual sites, and activation and entrainment mapping of previously unmappable VTs assisted by mechanical circulatory support devices, has overcome the limitations and greatly improved the success rates of catheter ablation. This review summarizes recent advances and novel approaches in both technology and techniques for catheter ablation of ventricular tachycardia.

KW - Arrhythmia

KW - Catheter ablation

KW - Heart failure

KW - ICD failure

KW - Intracardiac echocardiography

KW - Ventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=84893165214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893165214&partnerID=8YFLogxK

U2 - 10.1007/s11936-014-0297-2

DO - 10.1007/s11936-014-0297-2

M3 - Article

VL - 16

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 4

ER -